Everybody Wins in Health Care Reform Except You!
Politics / Healthcare Sector Dec 03, 2009 - 04:04 PM GMTBy: DailyWealth
"Everybody wins."
That's my theme for investing in health care in 2010.
As a biotech and health care investment advisor, I've spent over 100 hours in the past month digging through "ObamaCare"... finding the best and safest ways my readers can put their investment dollars to work in the sector. "Everybody wins" is the final result of my research.
I believe "everybody" – meaning just about every health care business you can think of – will win in the coming years because when you ignore the tiny details, political scare tactics, and other garbage spewing from the health care debate, you only need to know one figure to understand ObamaCare: 47 million new customers.
When the dust clears, as many as 47 million new patients will pour into the already massive U.S. health care industry.
Drugmakers, doctors, hospitals, insurance companies, pharmacies, device manufacturers – every health care business – will profit as our bloated system swells further. No taxes, regulations, forced concessions, or margin pressure will dampen the windfall from 47 million new consumers. And the majority of these new customers won't give a damn how much their care costs. Their neighbors will be paying for it.
So everybody will emerge a victor... with just one exception.
Who's the loser? You, the consumer.
Don't be fooled into thinking Washington and the health care industry are at odds over medical reform.
Conventional thinking says the private sector vehemently resists any government interference in free markets. As such, drugmakers, insurance companies, and other health care players should be fighting to keep legislators out of their business, right? From the surface, that appears to be the case.
This year, health care lobbyists are spending as much as $2 million a day pushing, prodding, and pampering legislators. Each lobbyist is striving to minimize the damage new reform will cause his client, while maximizing the benefit of tens of millions of uninsured joining the system. (Estimates on the exact number vary, but range between 30 million and 47 million.)
Through the third quarter of the year, the health care lobby had already outspent its entire 2008 outlay ($486 million). By the end of the year, the estimated $550 million tally will easily be the costliest advocacy campaign in U.S. history. But this superficial arm-twisting between special interest groups and lawmakers is no battle. It's a mating ritual.
Records show more than 350 former legislative staff and Congress members have crossed the divide as private-sector advocates. At least half of these insiders have direct work experience (including two former chiefs of staff) with Senators Max Baucus (D-Montana) and Chuck Grassley (R-Iowa), respectively the chairman and ranking member of the Senate Finance Committee, the most important group in shaping the health care reform bill.
And it's not only a one-way ticket from Congress to the private sector. Washington's revolving door routinely sucks players from industry into government roles, as well.
Luke Mitchell of Harper's magazine recently identified the driving force behind the Senate Finance Committee's reform agenda. It isn't Senator Baucus. Rather, it's Liz Fowler, Baucus' top aide and director of the committee's health care staff.
Fowler booked four years of political experience working for Baucus from 2001 to 2005. She left Washington for a high-paying job in the health care industry, as vice president of public policy and external affairs at WellPoint – one of the largest U.S. insurance companies. Then, "sensing that a Democratic-controlled Congress would make progress on overhauling the health care system," Fowler returned to Baucus' side in 2008 (as the Beltway gossip paper Politico wrote at the time).
Or consider Nancy-Ann DeParle, the so-called health care "czar" spearheading reform efforts for the White House. DeParle has a similar career path to Fowler's. Her former government jobs include director of what's now known as the Centers for Medicare and Medicaid Services, as well as a stint at the Office of Management and Budget under President Clinton.
But between Democratic presidents, DeParle jumped into the private sector. She served on the boards of several major health care firms, netting more than $6 million as director with medical device makers DaVita, Guidant, and Boston Scientific, health care IT company Cerner, Triad Hospital Systems, and others.
Never mind that during her directorship five of DeParle's companies paid more than $550 million in penalties for fraud, product liability, and antitrust matters – many of which involved tax dollars directly from Medicare and Medicaid.
As you can see, this is a dirty game. The players are making the rules. And everybody – but you – wins.
It will likely become the biggest government boondoggle ever conceived. In tomorrow's essay, I'll continue the story. You'll get more information on why you should be invested in health care right now... including my No. 1 favorite niche. My choice will surprise you.
Good investing,
Rob Fannon
The DailyWealth Investment Philosophy: In a nutshell, my investment philosophy is this: Buy things of extraordinary value at a time when nobody else wants them. Then sell when people are willing to pay any price. You see, at DailyWealth, we believe most investors take way too much risk. Our mission is to show you how to avoid risky investments, and how to avoid what the average investor is doing. I believe that you can make a lot of money – and do it safely – by simply doing the opposite of what is most popular.
Customer Service: 1-888-261-2693 – Copyright 2009 Stansberry & Associates Investment Research. All Rights Reserved. Protected by copyright laws of the United States and international treaties. This e-letter may only be used pursuant to the subscription agreement and any reproduction, copying, or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Stansberry & Associates Investment Research, LLC. 1217 Saint Paul Street, Baltimore MD 21202
Disclaimer: The above is a matter of opinion provided for general information purposes only and is not intended as investment advice. Information and analysis above are derived from sources and utilising methods believed to be reliable, but we cannot accept responsibility for any losses you may incur as a result of this analysis. Individuals should consult with their personal financial advisors.
Daily Wealth Archive |
© 2005-2022 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.
